MODERNA INC (MRNA) Stock Price, Forecast & Analysis
USA - NASDAQ:MRNA - US60770K1079 - Common Stock
MRNA Key Statistics, Chart & Performance
The current stock price of MRNA is 26.22 USD. In the past month the price decreased by -4.67%. In the past year, price decreased by -50.28%.
MRNA Latest News, Press Relases and Analysis
MRNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.02 | 384.37B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 149.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.26 | 109.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.32 | 68.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 878.57 | 58.73B | ||
| ARGX | ARGENX SE - ADR | 61.59 | 50.85B | ||
| INSM | INSMED INC | N/A | 39.27B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.24B | ||
| NTRA | NATERA INC | N/A | 27.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.86B | ||
| BIIB | BIOGEN INC | 9.19 | 22.55B |
Related stock screener links
About MRNA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Stephane Bancel
Employees: 5800
Phone: 16177146500
MODERNA INC / MRNA FAQ
What does MRNA do?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the stock price of MODERNA INC today?
The current stock price of MRNA is 26.22 USD. The price decreased by -3.46% in the last trading session.
Does MODERNA INC pay dividends?
MRNA does not pay a dividend.
How is the ChartMill rating for MODERNA INC?
MRNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for MRNA stock?
30 analysts have analysed MRNA and the average price target is 43.12 USD. This implies a price increase of 64.45% is expected in the next year compared to the current price of 26.22.
Can you provide the PE ratio for MRNA stock?
MODERNA INC (MRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.53).
Can you provide the growth outlook for MODERNA INC?
The Revenue of MODERNA INC (MRNA) is expected to decline by -41.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
MRNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MRNA. When comparing the yearly performance of all stocks, MRNA is a bad performer in the overall market: 91.12% of all stocks are doing better.
MRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRNA. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MRNA Financial Highlights
Over the last trailing twelve months MRNA reported a non-GAAP Earnings per Share(EPS) of -7.53. The EPS increased by 51.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.17% | ||
| ROE | -30.89% | ||
| Debt/Equity | 0 |
MRNA Forecast & Estimates
30 analysts have analysed MRNA and the average price target is 43.12 USD. This implies a price increase of 64.45% is expected in the next year compared to the current price of 26.22.
For the next year, analysts expect an EPS growth of -7.04% and a revenue growth -41.12% for MRNA